LAVA Therapeutics Expands Management Team with Three Key Appointments
09 nov. 2021 06h30 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
04 nov. 2021 07h00 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
02 nov. 2021 07h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE BREAST CANCER PARTNERSHIP RECEIVES NATIONAL ACCREDITATION
21 oct. 2021 15h23 HE
|
Florida Cancer Specialists & Research Institute
Davenport, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS), in collaboration with AdventHealth Heart of Florida and Central Florida Cancer...
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
15 oct. 2021 07h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and...
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference
13 sept. 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
24 août 2021 07h32 HE
|
HCW Biologics, Inc
Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance...
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE SURVEY FINDS CANCER PATIENTS SUPPORT COVID-19 VACCINE & MASK MANDATE
23 août 2021 12h13 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla, Aug. 23, 2021 (GLOBE NEWSWIRE) -- A survey of more than 6,800 cancer patients conducted this month by Florida Cancer Specialists & Research Institute (FCS) found that patients...
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
13 août 2021 07h10 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel...
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting
12 avr. 2021 07h00 HE
|
Medicenna Therapeutics Corp.
-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages -- Data demonstrate the potential to overcome...